about iatroX

Founder

Dr Kola TytlerMBBS CertHE MBA MRCGP

General Practitioner · Founder & Developer of iatroX

Forbes 30 Under 30 Europe · MSt Entrepreneurship, University of Cambridge

MBBS — King's College LondonMRCGP — Royal College of General PractitionersMBA (merit) — University of BirminghamMSt Entrepreneurship — University of CambridgeForbes 30 Under 30 EuropeMENSA MemberIBM-certified AI Engineer

Why iatroX exists

Before medicine, I built and scaled digital products to millions of users — learning how to ship fast, iterate with discipline, and think in systems. That engineering foundation sits behind every part of iatroX today.

Qualifying at King's College London and completing GP training in London, I saw first-hand how time pressure and knowledge fragmentation translate into cognitive overload at the point of care. iatroX is the tool I wanted to exist: a single, regulated platform that streamlines access to authoritative clinical information and helps clinicians and students retain what they learn, grounded in cognitive science rather than intuition.

What iatroX is

iatroX is a UKCA-marked, MHRA-registered Class I medical device. It brings together three capabilities in one platform: an AI clinical reference tool grounded in UK guidelines and international sources, an adaptive examination engine covering UK, US, Canadian and Australian boards and specialist diplomas, and integrated CPD tracking for UK clinicians.

The learning engine is built on peer-reviewed methods: active recall, spaced repetition, and adaptive sequencing. These are not buzzwords — they are the learning mechanisms with the strongest evidence base for long-term retention, and iatroX applies them automatically so clinicians and students don't just find information, they retain it.

Whether you are a GP, a specialist trainee preparing for a diploma, an international medical graduate adapting to a new system, or a pharmacy student sitting the GPhC CRA — iatroX is designed to close the gap between knowledge and action.

iatroX is built under a disciplined, regulatory-grade development process: UKCA-marked and MHRA-registered as a Class I medical device, with published technical methodology, a peer-reviewed arXiv research paper, and established data partnerships. Clinical content is mapped to current UK guidance and reviewed against the associated exam blueprints.

300,000+ questions answered — and counting

Where iatroX is going

The goal is broad adoption across healthcare systems worldwide — to make evidence-based guidance second nature at the point of care rather than a time-consuming barrier. The roadmap extends from UK specialist diplomas and the GPhC pharmacy vertical into deeper clinical reference, CPD, and institutional deployments for NHS Trusts, deaneries and medical schools.